Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

By |2019-05-09T14:49:00-05:00May 9th, 2019|Categories: DSF Research Review|Tags: , , , , , , |

A number of publications have appeared recently reporting on the efficacy and safety of cannabidiol (CBD) as an add-on therapy, as its clinical trials are concluding and its use is extending.  This paper describes an "expanded access" program - that is, when the FDA allows access to a drug before approval.  This is of [...]

Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome

By |2017-07-09T15:56:26-05:00July 9th, 2017|Categories: DSF Research Review|Tags: , |

(Devinsky, et al. 2017) The long-anticipated results from the first randomized, double blind, placebo controlled trial of cannabidiol (CBD) in Dravet syndrome show that cannabidiol can help alleviate seizures in this syndrome. While there have been anecdotal stories of success with CBD in Dravet syndrome since as early as 2012, this trial represents the first [...]